share_log

藥明生物：有關連接子及有效載荷主服務協議之 持續關連交易

WUXI BIO: CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE PAYLOAD-LINKERS MASTER SERVICES AGREEMENT

香港交易所 ·  Apr 1 19:19
Summary by Futu AI
藥明生物宣布，其子公司藥明合聯與藥明康德集團簽訂連接子及有效載荷主服務協議，自2023年11月17日起至2025年12月31日止，並可續期三年。該協議涉及向藥明合聯集團提供研發及製造服務，以及供應ADC CRDMO服務使用的相關中間產品。由於藥明合聯的相關百分比率超過10%，根據2023年全年業績，藥明合聯不再被視為非重大附屬公司，因此本次交易需遵守上市規則第14A章的申報及公告規定，但獲豁免遵守通函、獨立財務意見及股東批准的規定。過去三年，藥明合聯集團就此服務產生的總金額分別為人民幣21.9百萬元、132.9百萬元及148.1百萬元，並設定了2024年及2025年的年度上限分別為人民幣182.0百萬元及168.0百萬元。藥明生物為全球生物藥CRDMO，提供端到端解決方案，而藥明康德為全球醫藥研發服務平台，專注於創新藥物的發現、開發及製造。
藥明生物宣布，其子公司藥明合聯與藥明康德集團簽訂連接子及有效載荷主服務協議，自2023年11月17日起至2025年12月31日止，並可續期三年。該協議涉及向藥明合聯集團提供研發及製造服務，以及供應ADC CRDMO服務使用的相關中間產品。由於藥明合聯的相關百分比率超過10%，根據2023年全年業績，藥明合聯不再被視為非重大附屬公司，因此本次交易需遵守上市規則第14A章的申報及公告規定，但獲豁免遵守通函、獨立財務意見及股東批准的規定。過去三年，藥明合聯集團就此服務產生的總金額分別為人民幣21.9百萬元、132.9百萬元及148.1百萬元，並設定了2024年及2025年的年度上限分別為人民幣182.0百萬元及168.0百萬元。藥明生物為全球生物藥CRDMO，提供端到端解決方案，而藥明康德為全球醫藥研發服務平台，專注於創新藥物的發現、開發及製造。
Pharma Biologics announced that its subsidiary Pharmaceutical Union and Pharma Kond Group have entered into a Connective Subsidiary and Active Carrier Service Agreement from 17 November 2023 to 31 December 2025 for a period of three years. The agreement involves the provision of R&D and manufacturing services to the Pharmaceutical Joint Group and the supply of related intermediate products for use in ADC CRDMO services. As the relevant percentage of Pharma Union exceeds 10%, according to its 2023 annual results, Pharmaceutical Union is no longer considered a non-significant subsidiary. Therefore, this transaction is subject to the declarations and announcements of Chapter 14A of the Listing Rules, but is exempt from compliance with the requirements of circulars, independent financial opinions and shareholder approval. In the past...Show More
Pharma Biologics announced that its subsidiary Pharmaceutical Union and Pharma Kond Group have entered into a Connective Subsidiary and Active Carrier Service Agreement from 17 November 2023 to 31 December 2025 for a period of three years. The agreement involves the provision of R&D and manufacturing services to the Pharmaceutical Joint Group and the supply of related intermediate products for use in ADC CRDMO services. As the relevant percentage of Pharma Union exceeds 10%, according to its 2023 annual results, Pharmaceutical Union is no longer considered a non-significant subsidiary. Therefore, this transaction is subject to the declarations and announcements of Chapter 14A of the Listing Rules, but is exempt from compliance with the requirements of circulars, independent financial opinions and shareholder approval. In the past three years, the total amount generated by the Pharmaceutical Joint Group for this service was RMB21.9 million, $132.9 million and $148.1 million, respectively, and set a ceiling of RMB182.0 million and RMB168.0 million for the years 2024 and 2025, respectively. Pharma Biologics is a global biopharmaceutical CRDMO, providing end-to-end solutions, while Pharma Kund is a global pharmaceutical R&D service platform focused on the discovery, development and manufacturing of innovative medicines.

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.